NCT01254396

Pharmacokinetics Of Sildenafil Orally Disintegrating Tablet Formulation Given With Or Without Food.

An Open Label Crossover Study In Healthy Older Male Subjects To Evaluate The Pharmacokinetics And Safety Of An Orally Disintegrating Tablet Formulation Of Sildenafil Administered Without Water Under Fed Compared To Fasted Conditions

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
• Sex: Male
• Age: 45 Years
• Healthy volunteers: Accepted

Summary

This study will evaluate if an orally disintegrating tablet of sildenafil will have similar pharmacokinetic properties when given with food and without food.

Conditions

• Erectile Dysfunction

Interventions

Type	Name	Description
DRUG	Sildenafil	Orally Disintegrating Tablet, 50 mg, Single Dose
DRUG	Sildenafil	Orally Disintegrating Tablet, 50 mg, Single Dose

Timeline

• Start date: 2010-12-01
• Primary completion: 2011-01-01
• Completion: 2011-01-01
• First posted: 2010-12-06
• Last updated: 2021-02-01
• Results posted: 2012-02-08

Locations

1 site across 1 country: Singapore